Cyprus Mail

EU unsure if women face higher risk of clots from AZ vaccine

file photo: vial labelled "astrazeneca coronavirus disease (covid 19) vaccine" placed on displayed eu flag is seen in this illustration picture
Vial labelled "AstraZeneca coronavirus disease (COVID-19) vaccine" placed on displayed EU flag

The European Union’s drugs regulator could not confirm from available data if women and young adults were at a higher risk of rare blood clots with low platelets after vaccination with AstraZeneca’s COVID-19 shot.

Limitations in the way the data was collected meant that the European Medicines Agency (EMA) could not identify any specific risk factor that made the condition, thrombosis with thrombocytopenia syndrome (TTS), more likely, it said on Friday.

The European Commission had requested scientific opinion from the EMA after reports of TTS associated with the vaccine, Vaxzevria, earlier this year, which led to many EU states suspending use of the shot once considered key to the region’s inoculation plans.

The EMA said it was reiterating that the second dose of the two-shot vaccine, developed along with the University of Oxford, continued to be given between four and 12 weeks after the first.

“There is no evidence that delaying the second dose has any influence on the risk of TTS,” the EMA said.

It also said that no definitive recommendations could be currently given on the use of a different vaccine for a second dose following a first with AstraZeneca’s shot.

Related Posts

UK pushes ahead with Rwanda migrant scheme as small boats keep coming

Reuters News Service

Senior Kenyan election officials disown the results of presidential election

Reuters News Service

Russia says it will facilitate IAEA visit to Ukrainian nuclear plant

Reuters News Service

Pfizer CEO Bourla catches Covid

Reuters News Service

White House seeks to improve Biden’s low ratings ahead of midterms

Reuters News Service

Saudi prince made $500m Russia bet at start of Ukraine war

Reuters News Service